Dubos-Arvis, C. (C.)

Filtering

2018 - 20192

Settings

Author search.filters.isAuthorOfPublication.27a943f6-194c-44e8-9e89-e1c545844cdd

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro
    (Elsevier, 2018) Dubos-Arvis, C. (C.); Perez-Gracia, J.L. (Jose Luis); Kim, D.W; Baas, P. (P.); Lubiniecki, G.M (G. M.); Novello, S. (S.); Samkari, A. (A.); Chul-Cho, B. (B.); Su, W.C. (W. C.); Gubens, M.A. (M. A.); Han, J.Y. (J. Y.); Herbst, R.S. (Roy S.); Garon, E.B. (E. B.); Szalai, Z. (Z.); Majem-Tarruella, M. (Margarita); Ceresoli, G.L. (G. L.); Jensen, E.H. (E. H.); Forster, M. (M.); Monnet, I. (I.)
    In the global, open-label, phase 2/3 study KEYNOTE-010, pembro 10 mg/kg or 2 mg/kg Q3W improved OS vs docetaxel in pts with previously treated advanced NSCLC with PD-L1 TPS ≥50% and ≥1% (coprimary analyses) at median follow-up of 13.1 mo. We present long-term results overall, in pts who completed 35 cycles (∼2 y) of pembro, and in pts who received a second course of pembro.
  • Thumbnail Image
    Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
    (Elsevier BV, 2019) Fidler, M.J. (M. J.); Emancipator, K. (K.); Dubos-Arvis, C. (C.); Garrido, M. (M.); Perez-Gracia, J.L. (Jose Luis); Felip, E. (Enriqueta); Kim, D.W; Kim, J.H. (J. H.); Castro-Jr, G. (G.) de; Baas, P. (P.); Lubiniecki, G.M (G. M.); Samkari, A. (A.); Han, J.Y. (J. Y.); Surmont, V. (V.); Herbst, R.S. (Roy S.); Garon, E.B. (E. B.); Ahn, M.J. (M. J.); Molina, J.R. (J. R.); Majem-Tarruella, M. (Margarita); Jensen, E.H. (E. H.); Shentu, Y. (Y.)
    Background: In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced non-small-cell lung cancer (NSCLC). A prespecified exploratory analysis compared outcomes in patients based on PD-L1 expression in archival versus newly collected tumor samples using recently updated survival data. Patients and methods: PD-L1 was assessed centrally by immunohistochemistry (22C3 antibody) in archival or newly collected tumor samples. Patients received pembrolizumab 2 or 10 mg/kg Q3W or docetaxel 75 mg/m2 Q3W for 24 months or until progression/intolerable toxicity/other reason. Response was assessed by RECIST v1.1 every 9 weeks, survival every 2 months. Primary end points were OS and progression-free survival (PFS) in tumor proportion score (TPS) ≥50% and ≥1%; pembrolizumab doses were pooled in this analysis. Results: At date cut-off of 24 March 2017, median follow-up was 31 months (range 23-41) representing 18 additional months of follow-up from the primary analysis. Pembrolizumab versus docetaxel continued to improve OS in patients with previously treated, PD-L1-expressing advanced NSCLC; hazard ratio (HR) was 0.66 [95% confidence interval (CI): 0.57, 0.77]. Of 1033 patients analyzed, 455(44%) were enrolled based on archival samples and 578 (56%) on newly collected tumor samples. Approximately 40% of archival samples and 45% of newly collected tumor samples were PD-L1 TPS ≥50%. For TPS ≥50%, the OS HRs were 0.64 (95% CI: 0.45, 0.91) and 0.40 (95% CI: 0.28, 0.56) for archival and newly collected samples, respectively. In patients with TPS ≥1%, OS HRs were 0.74 (95% CI: 0.59, 0.93) and 0.59 (95% CI: 0.48, 0.73) for archival and newly collected samples, respectively. In TPS ≥50%, PFS HRs were similar across archival [0.63 (95% CI: 0.45, 0.89)] and newly collected samples [0.53 (95% CI: 0.38, 0.72)]. In patients with TPS ≥1%, PFS HRs were similar across archival [0.82 (95% CI: 0.66, 1.02)] and newly collected samples [0.83 (95% CI: 0.68, 1.02)]. Conclusion: Pembrolizumab continued to improve OS over docetaxel in intention to treat population and in subsets of patients with newly collected and archival samples.